Dmitry Kaminskiy speaks as though he were trying to unload everything he knows about the science and economics of longevity—from senolytics research that seeks to stop aging cells from spewing inflammatory proteins and other molecules to the trillion-dollar life extension industry that he and his colleagues are trying to foster—in one sitting.

At the heart of the discussion with Singularity Hub is the idea that artificial intelligence will be the engine that drives breakthroughs in how we approach healthcare and healthy aging—a concept with little traction even just five years ago.

“At that time, it was considered too futuristic that artificial intelligence and data science … might be more accurate compared to any hypothesis of human doctors,” said Kaminskiy, co-founder and managing partner at Deep Knowledge Ventures, an investment firm that is betting big on AI and longevity.